L-N-acetyl-alanine n-butyl ester | 2256-78-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-N-acetyl-alanine n-butyl ester
• 英文别名: N-acetylalanine butyl ester；butyl (2S)-2-acetamidopropanoate
• CAS: 2256-78-2
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: RDSNYYQDMRAFHN-ZETCQYMHSA-N

物化性质

• 沸点：
  298.3±13.0 °C(Predicted)
• 密度：
  1.001±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (S)-2-氨基丙酸丁酯 、 乙酸酐 在 吡啶 作用下， 生成 L-N-acetyl-alanine n-butyl ester
  参考文献：
  名称：

  面包酵母的对映体选择性水解-II：正乙酰基氨基酸的酯1

  摘要：

  DN-乙酰基氨基酸酯是通过使用发酵酵母通过其外消旋物的对映体选择性水解而获得的。有证据表明蛋白酶是所涉及的酶。

  DOI：

  10.1016/s0040-4020(01)90011-0

文献信息

• Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products
  申请人：——

  公开号：US20030228259A1

  公开（公告）日：2003-12-11

  Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.

  本发明公开了确定生物分子生物合成或分解速率的方法，具体为通过取样可获取的生物样本中的代谢衍生物和分解产物，测量难以或不易直接取样的生物分子的生物合成和分解速率。
• LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM
  申请人：BARYZA Jeremy

  公开号：US20110200582A1

  公开（公告）日：2011-08-18

  Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.

  本文披露了用于将生物活性剂量有效传递至肝脏、肿瘤和/或其他细胞或组织的配方和优化方案。还提供了具有化学式（I）的阳离子脂质化合物的组成和用途。该发明还涉及具有化学式（XI）的隐身脂质的组成和用途。还提供了制备这种化合物、组成物和配方的方法，以及利用这些化合物、组成物和配方将生物活性剂传递至细胞和/或组织的方法和用途。
• LIPIDS, LIPID COMPOSITIONS AND METHODS OF USING THEM
  申请人：Novartis AG

  公开号：EP3721943A1

  公开（公告）日：2020-10-14

  Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.

  公开了向肝脏、肿瘤和/或其他细胞或组织输送治疗有效量的生物活性剂的配方和优化方案。还提供了式 (I) 阳离子脂质化合物的组合物和用途。本发明还涉及式（XI）隐形脂质的组合物和用途。本发明还提供了制造此类化合物、组合物和制剂的工艺，以及使用此类化合物、组合物和制剂向细胞和/或组织递送生物活性剂的方法和用途。
• COMPOUNDS FOR PROTEASOME ENZYME INHIBITION
  申请人：Proteolix, Inc.

  公开号：EP1745064B1

  公开（公告）日：2011-01-05
• UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY
  申请人：Five Eleven Pharma Inc.

  公开号：US20170189568A1

  公开（公告）日：2017-07-06

  The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [ 68 Ga]GaCl 3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.